Oregon Public Employees Retirement Fund Decreases Holdings in Catalent, Inc. (NYSE:CTLT)

Oregon Public Employees Retirement Fund lowered its stake in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,701 shares of the company’s stock after selling 248 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Catalent were worth $991,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of CTLT. CX Institutional acquired a new position in shares of Catalent during the second quarter valued at approximately $37,000. Clear Street Markets LLC increased its position in shares of Catalent by 408.1% during the second quarter. Clear Street Markets LLC now owns 376 shares of the company’s stock worth $40,000 after purchasing an additional 302 shares in the last quarter. Alta Advisers Ltd purchased a new position in Catalent in the 3rd quarter valued at $43,000. Selective Wealth Management Inc. acquired a new stake in Catalent during the 2nd quarter worth $57,000. Finally, Wipfli Financial Advisors LLC purchased a new stake in shares of Catalent during the third quarter worth $58,000. Institutional investors and hedge funds own 99.38% of the company’s stock.

Insider Activity at Catalent

In other news, insider Manja Boerman sold 780 shares of the stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the sale, the insider now owns 15,860 shares of the company’s stock, valued at $819,962. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Manja Boerman sold 780 shares of Catalent stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the transaction, the insider now owns 15,860 shares of the company’s stock, valued at approximately $819,962. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by company insiders.

Catalent Stock Performance

Shares of CTLT stock opened at $52.59 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86. The firm has a market cap of $9.46 billion, a P/E ratio of 22.47, a P/E/G ratio of 3.41 and a beta of 1.24. The firm’s 50 day moving average price is $46.21 and its 200-day moving average price is $72.48. Catalent, Inc. has a one year low of $40.69 and a one year high of $115.33.

Catalent (NYSE:CTLT – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.24). Catalent had a return on equity of 12.55% and a net margin of 8.83%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. As a group, equities research analysts predict that Catalent, Inc. will post 2.93 EPS for the current year.

Analyst Ratings Changes

CTLT has been the topic of a number of recent research reports. KeyCorp lowered their price target on shares of Catalent from $125.00 to $85.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 2nd. Morgan Stanley dropped their price target on Catalent from $120.00 to $81.00 and set an “overweight” rating for the company in a research report on Thursday, November 3rd. Robert W. Baird lowered their price objective on Catalent from $123.00 to $75.00 in a research note on Wednesday, November 2nd. Barclays cut their target price on Catalent from $105.00 to $62.00 and set an “overweight” rating for the company in a research note on Wednesday, November 2nd. Finally, Argus cut shares of Catalent from a “buy” rating to a “hold” rating in a research report on Monday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Catalent currently has a consensus rating of “Hold” and an average price target of $92.80.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.